



INNOVATION IN RADIO-ONCOLOGY COURSE

1-3 March 2017
Tel Aviv, Israel

Chairs: J. Bernier, CH - F.A. Calvo, ES

Host Chair: A. Kuten, IL

Scientific Coordinators: Z. Symon, IL

Y. Belkacemi, FR

Local Committee: A. Kuten, IL - R.L. Pfeffer, IL

R. Bar-Deroma, IL - T. Katzman, IL - F. Atrash, IL

Held in collaboration with



With the support of



SECOND ANNOUNCEMENT

FOREWORD

This 3-day ESO course is dedicated to clinical, technical and biological innovations in the management of cancer with emphasis on radiation oncology. "Hot" topics such as single and hypo-fractionated RT, stereotactic brain and body RT, focal RT, particle RT, radiobiology of hypo-fractionation, SBRT and particle RT, the scientific basis of immunotherapy, combination of RT and immunotherapy and targeted therapies will be discussed. In addition, local Israeli high-tech achievements and innovations in basic and applied cancer research will be presented.

LEARNING OBJECTIVES

- Update the knowledge in radiobiology, hypofractionated, stereotactic brain and body RT, focal RT, particle RT, the scientific basis of immunotherapy and combined RT - immunotherapy and targeted therapies.
- Become aware of innovative strategies in radiation oncology and combined modality therapy of cancer
- Learn how to incorporate the innovative strategies in daily practice

OFFICIAL LANGUAGE

The course will be held in English and no translation will be provided.

BADGE

The name badge is the only official evidence of registration and should be worn at all times during the Conference

INSURANCE

The organisers bear no responsibility for untoward events in relation to the participation in the course. Participants are advised to take out their own personal and travel insurance.

CME ACCREDITATION

Participants will be entitled to receive a certificate of attendance at the close of the Conference by completing the online evaluation questionnaire.

The event has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS). The evaluation of the event has been performed by the Accreditation Council of Oncology in Europe (ACOE) that acknowledged the quality of the scientific programme and its educational value.

The event is designated for a maximum of **15 European CME credits** (ECMEC).

Through an agreement between UEMS and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.

FACULTY

- A. Alezra**, Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv, IL
- A. Alon**, Radiation Oncology, Davidoff Oncology Institute, Rabin Med Ctr, Petach Tiqva, IL
- U. Amit**, Sheba Medical Center and Sackler School of Medicine, Tel Aviv, IL
- F. Atrash**, Dept of Radiation Therapy, Augusta Victoria Hospital, East Jerusalem, IL
- R. Bar-Deroma**, Dept. of Oncology, Rambam Health Care Campus, Haifa, IL
- Y. Belkacemi**, Dept. of Radiation Oncology, Hopitaux Universitaires Henri Mondor, Creteil, FR
- M. Ben David**, Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv, IL
- S. Ben-Haim**, Nuclear Medicine, Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv, IL
- R. Ben Yoseph**, Rambam Healthy Care Campus, Faculty of Medicine, Technion, Haifa, IL
- J. Bernier**, Dept. of Radio Oncology, Swiss Medical Network, Genolier Clinic, Genolier, CH
- D. Blumental**, Tel Aviv Medical Center, Tel Aviv, IL
- F.A. Calvo**, Hospital General Universitario Gregorio Marañon, Madrid, ES
- L. Domachevsky**, Dept. of Radiology and Nuclear Medicine, Assuta Medical Centers, Tel Aviv, IL
- E. Even-Sapir**, Nuclear Medicine, Tel Aviv Med Ctr, and Sackler School of Medicine, Tel Aviv, IL
- E. Gez**, Radiation Oncology, Tel Aviv Medical Center, Tel Aviv, IL
- J. Gligorov**, Dept. of Medical oncology, Tenon Hospital, Paris, FR
- T. Katzman**, Dept. Radiation Oncology, Chaim Sheba Medical Center, Tel Hashomer, IL
- A. Kuten**, Dept. of Oncology, Italian Hospital Haifa, Haifa, IL
- Y.R. Lawrence**, Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv, IL
- R. Leibowitz-Amit**, Dept. of Medical Oncology, Oncology Institute and Cancer Research Center, Tel Hashomer, IL
- D. Levin**, Dept. of Radiotherapy, Assuta Medical Centers, Tel Aviv, IL
- O. Luxenburg**, Director of Medical Technologies and Infrastructure Administration at Ministry of Health, Jerusalem, IL
- A.J. Lomax**, Dept. of Radiation Therapy, Paul Scherrer Institute, Villigen, CH
- M. Marash**, P-Cure Ltd – Patient Centric Proton Therapy, Lod, IL
- G. Markel**, Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv, IL
- R. Miralbell**, Serv. De Radio-Oncologie, Hopitaux Universitaires, Geneva, CH
- F. Peccatori**, Scientific Director, European School of Oncology (ESO), Milan, IT
- M. Ozsahin**, Centre Hospitalier Universitaire Vaudois, Lausanne, CH
- R. Pfeffer**, Assuta Medical Centers, Tel Aviv, IL
- M. Pruschy**, Laboratory for Molecular Radiobiology, Dept. Radiation Oncology University Hospital, Zurich, CH
- G. Rechavi**, Sheba Medical Center, Djerassi Chair in Oncology, Tel Aviv, IL
- Z. Symon**, Dept. Radiation Oncology, Chaim Sheba Medical Center, Tel Aviv, IL
- R. Spiegelman**, Sheba medical Center and Assuta Hospitals, Ramat Gan, Tel Aviv, IL
- Y. Tova**, Assuta Medical Centers, Tel Aviv, IL
- T. Tzuk**, Rambam Health Care Campus, Faculty of Medicine, Technion, Haifa, IL
- D.C. Weber**, Dept of Radiation Therapy, Paul Scherrer Institute, Villigen, CH
- N. Weizman**, Dept. of Radiation Oncology, Chaim Sheba Medical Center, Beer Sheva, IL
- M. Wygoda**, Radiation Oncology, Hadassah Medical Center, Hebrew University, Jerusalem, IL
- L. Zach**, Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, IL
- A. Ziv**, MSR – Israel Center for Medical Simulation, Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, IL
- A. Zigler**, High Intensity Laser Lab and Chair of Physics, Hebrew University of Jerusalem, IL

PROGRAMME

Wednesday, 1 March

8:00 Welcome and opening address

A. Kuten, IL - J. Bernier, CH - F.A. Calvo, ES - Z. Symon, IL

J. Gligorov, FR - O. Luxenburg, IL - M. Ziv, IL - W. Mermershtain, IL

F. Peccatori, IT

MULTIMODALITY IMAGING FOR MODERN RADIOTHERAPY PLANNING

Chair: L. Domachevsky, IL

8:30 Why MRI is needed in radiotherapy planning and re-irradiation

L. Zach, IL

9:00 Role of MRI planning of prostate cancer

R. Miralbell, CH

9:30 Role of PET CT/PET MRI for target volume definition

(Breast, lung, cervix, lymphoma)

S. Ben-Haim, IL

9:50 Role of PET MRI

M. Ozsahin, CH

10:15 From molecular imaging to targeted therapy:

The story of PSMA and PRRT

E. Even-Sapir, IL

10:45 *Coffee break*

MANAGING MOTION IN RADIOTHERAPY

Chair: R. Bar-Deroma, IL

11:00 Managing motion in radiotherapy: principles and practice

D. Levin, IL

12:00 Innovation - beyond breath hold - improving geometry by
respiratory intervention: CPAP and other strategies

N. Weizman, IL

12:30 *Lunch*

STEREOTACTIC BODY RADIATION THERAPY

Chair: A. Alon, IL

13:30 Overview of SBRT trials for oligometastases

R. Pfeffer, IL

14:15 Prostate SBRT and focal RT:

Early results from European multicentric study

R. Miralbell, CH

15:00 SBRT in pain management: New horizons

Y.R. Lawrence, IL

15:30 *Coffee break*

BRAIN METASTASIS: NEW PARADIGMS

Chair: T. Tzuk, IL

16:00 SRS vs WBRT vs no RT, a multidisciplinary approach and
overview of trials

L. Zach, IL

16:45 Radiosurgery for multiple brain metastasis: Current technologies

R. Pfeffer, IL

R. Spiegelman, IL

17:15 TKI, Braf and other "biologicals" for brain metastasis:

How to use with radiotherapy?

D. Blumental, IL

17:45- Case presentation and panel discussion

(all of the above speakers)

18:30

PARTICLE THERAPY: 2016 AND BEYOND (PART I)

Chair: M. Ozsahin, CH

- 8:30** Overview of proton facilities:
What is commercially available and what is in the pipeline? A.J. Lomax, CH
- 9:30** Radiobiology of low-LET protons and photons:
Early reports on differential responses mechanisms M. Pruschy, CH
- 10:00** Present and future indications for PT D.C. Weber, CH
- 10:45** *Coffee break*

PARTICLE THERAPY: 2016 AND BEYOND (PART II)

Chair: E. Gez, IL

- 11:00** Innovation: P cure M. Marash, IL
- 11:15** Innovation: "Tabletop" laser generated protons A. Zigler, IL
- 11:30** Innovation: Creating "bragg peak" like electrons A. Alezra, IL
- 11:45** Focused ultrasound (Insightech) R. Pfeffer, IL
- 12:00** **Panel: New technologies in RT**
J. Bernier, CH - R. Miralbell, CH - D.C. Weber, CH - Z. Symon, IL
R. Pfeffer, IL - R. Bar Deroma, IL - A.J. Lomax, CH - M. Ozsahin, CH
- 12:30** *Lunch*

**NEW HORIZONS IN PERSONALIZED MEDICINE AND IMMUNOTHERAPY
FOR CANCER (PART I)**

Chair: J. Gligorov, FR

- 13:30** The role of RNA epigenetics in cancer G. Rechavi, IL
- 14:15** Overview of state-of-the-art immunotherapy
(including Ceacam 1) G. Markel, IL
- 15:15** Understanding the toxicities of modern immunotherapy R. Leibowitz-Amit, IL
- 15:45** *Coffee break*

**NEW HORIZONS IN PERSONALIZED MEDICINE AND IMMUNOTHERAPY
FOR CANCER (PART II)**

Chair: F. Atrash, IL

- 16:00** Immunotherapy agents and radiotherapy:
Results and ongoing clinical trials Abscopal effect of RT –
from the lab to clinical practice U. Amit, IL
- 16:45-17:15** Bio-dosimetry and personalized radiotherapy Y.R. Lawrence, IL

RADIOBIOLOGY OF HYPOFRACTIONATED RT AND SBRT

Chair: Y. R. Lawrence, IL

- 8:30

Radiobiology of hypofractionation and SBRT:
cellular and tissue level

M. Pruschy, CH
- 9:15

Hypofractionation for breast cancer:
Tumor control and normal tissue complications

M. Ben David, IL
- 9:45

Hypofractionation for prostate cancer:
Tumor control and normal tissue complications

M. Wygoda, IL
- 10:15

Coffee break

APBI AND INTRAOPERATIVE RT

Chair: Y. Tova, IL

- 10:30

IORT for primary breast cancer: A critique

Y. Belkacemi, FR
- 11:00

Intraoperative electron boost in polyvalent indications:
30 years' results and innovative technologies

F.A. Calvo, ES

RT IN THE MEDITERRANEAN AREA AND EDUCATION

Chair: R. Ben Yoseph, IL

- 11:30

Radiation oncology - need and availability around the
Mediterranean area

Y. Belkacemi, FR
- 11:45

The power and the impact of simulation in medical education
for the next generation

A. Ziv, IL
- 12:15

A new approach for radiotherapy education in small and
medium size countries: Moving forward from IEAA
train-the-trainers

T. Katzman, IL
- 12:30

Closing ceremony
- 12:45

Lunch

GENERAL INFORMATION

ORGANISING SECRETARIAT

European School of Oncology
Via Turati 29 | 20121 Milan | Italy
Francesca Marangoni
E-mail: fmarangoni@eso.net | Phone: +39 02 85464525

LOCAL ORGANISER AND REGISTRATION

I.M. Knasim Ltd
Tel Aviv, Israel
Ayelet Levy
knasim@imknasim.co.il
Tel: +972-3-6081520 - Fax: +972-3-6081522

VENUE

Leonardo City Tower Hotel
Zisman Shalom St 14, Ramat Gan, Tel Aviv, Israel
<http://leonardo-city-tower.hotel-rn.com>

HOTEL ACCOMMODATION

Accommodation at the course venue (Leonardo City Tower Hotel) may be reserved through I.M. Knasim. For further information, please contact knasim@imknasim.co.il.

REGISTRATION

Registration is available by returning the enclosed Registration Form filled in to I.M. Knasim. The registration fee includes participation in all sessions, coffee breaks and lunches as described in the programme and access to the event-dedicated website.

Pre-registration fees (Israeli shekels) are available till **13 February**.

REGISTRATION FEES: (Israeli shekels)

	Pre-registration (by 13 February 2017)	On site (from 14 February 2017)
Regular fee	IS 200	IS 300
Discounted fee* (see below)	IS 120	IS 180

* Resident doctors in training, physicists, radiotherapy technologists, nurses, cancer biologists, dosimetrists

* Discounted fee for participants from lower- and upper-middle-income economies as defined by The World Bank

CANCELLATION OF REGISTRATION

To qualify for the refund of the registration fee, cancellation should be notified to I.M. Knasim in writing by 13 February 2017.

REGISTRATION FORM - INNOVATION IN RADIO-ONCOLOGY COURSE | 1-3 March 2017 | Tel Aviv | IsraelPlease fill in this form in BLOCK CAPITALS and send by **13 February** to:

I.M. Knasim Ltd | Attn. Mrs. Ayelet Levy | 132 Menachem Begin Blvd. | Tel Aviv 6701101 | Israel

E mail: knasim@imknasim.co.il | Tel: +972-3-6081520 | Fax: +972-3-6081522**PARTICIPANT'S DETAILS**☐ Dr. ☐ Prof. ☐ Mrs. ☐ Mr.

Family name First name

Institute

Department

Street

Zip Code Town Country

Phone Fax Mobile

Email

Profession

Specialisation Main field

VAT number (*compulsory for self-employed persons*)Fiscal code (*Italian residents only*)**If your invoice details are different to those above, please complete the following section:**

Invoice contact person

Address

Phone email

VAT number (*compulsory for self-employed persons*)Fiscal Code (*Italian residents only*)**Pre-registration fees** (Israeli shekels) are available till **13 February**

	Pre-registration (by 13 February 2017)	On site (from 14 February 2017)
Regular fee	<input type="checkbox"/> IS 200	<input type="checkbox"/> IS 300
Discounted fee	<input type="checkbox"/> IS 120	<input type="checkbox"/> IS 180

PAYMENT DETAILS:**The registration is processed when payment accompanies the form (*credit card details or copy of bank transfer*)**☐ Visa/Mastercard Card Number / / /
Expire date / CV2 code

Holder's name: and signature

☐ **BANK TRANSFER** with no cost to the beneficiary (please provide a copy of the bank transfer):**Bank:** UBank Ltd. | 38 Rothschild Blvd. | Tel Aviv | Bank no. 26 | Branch 287**Beneficiary:** A.M. Assemblies Ltd**Account number:** 776831**IBAN:** IL370262870000000776831 | **SWIFT CODE:** FIRBIL21**Reference:** "Radio-oncology course" + participant's nameUnless written objection is made, participants authorise ESO to use their personal data according to the regulation as specified in Article 13 DLGS 196, available at www.eso.net or on request at fax number +39 02 8546 4545.

Signature Date